Conditions: Schizophrenia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 103
Healthy volunteers: no

Brief summary:
This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in subjects with schizophrenia.

Detailed description:
B7441007 is a randomized, double-blind, placebo-controlled, sponsor open, parallel group design, Phase 1b study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of 3 doses of PF-06412562 (3 mg BID, 9 mg BID and 45 mg BID) over 15 days in approximately 100 psychiatrically stable (as defined by the inclusion and exclusion criteria) subjects with schizophrenia are on background treatment with SOC antipsychotics and other psychotropic medications.

All doses will be administered twice daily, with approximately 12 hours between each dose.

Arms:
arm 1: PF-06412562 3mg BID arm 2: PF-06412562 9mg BID arm 3: PF-06412562 45mg BID arm 4: Placebo BID

Interventions: intervention 1: PF-06412562 3mg BID intervention 2: PF-06412562 9mg BID intervention 3: PF-06412562 45mg BID intervention 4: Placebo
Intervention descriptions: intervention 1: PF-06412562 intervention 2: PF-06412562 intervention 3: PF-06412562 intervention 4: Placebo

Protocol document: